Literature DB >> 12944176

Potential urinary and plasma biomarkers of peroxisome proliferation in the rat: identification of N-methylnicotinamide and N-methyl-4-pyridone-3-carboxamide by 1H nuclear magnetic resonance and high performance liquid chromatography.

Stephanie Ringeissen1, Susan C Connor, H Roger Brown, Brian C Sweatman, Mark P Hodson, Steve P Kenny, Richard I Haworth, Paul McGill, Mark A Price, Mike C Aylott, Derek J Nunez, John N Haselden, Catherine J Waterfield.   

Abstract

This study identified two potential novel biomarkers of peroxisome proliferation in the rat. Three peroxisome proliferator-activated receptor (PPAR) ligands, chosen for their high selectivity towards the PPARalpha, -delta and -gamma subtypes, were given to rats twice daily for 7 days at doses known to cause a pharmacological effect or peroxisome proliferation. Fenofibrate was used as a positive control. Daily treatment with the PPARalpha and -delta agonists produced peroxisome proliferation and liver hypertrophy. 1H nuclear magnetic resonance spectroscopy and multivariate statistical data analysis of urinary spectra from animals given the PPARalpha and -delta agonists identified two new potential biomarkers of peroxisome proliferation--N-methylnicotinamide (NMN) and N-methyl-4-pyridone-3-carboxamide (4PY)--both endproducts of the tryptophan-nicotinamide adenine dinucleotide (NAD+) pathway. After 7 days, excretion of NMN and 4PY increased 24- and three-fold, respectively, following high doses of fenofibrate. The correlation between total NMN excretion over 7 days and the peroxisome count was r=0.87 (r2=0.76). Plasma NMN, measured using a sensitive high performance liquid chromatography method, was increased up to 61-fold after 7 days' treatment with high doses of fenofibrate. Hepatic gene expression of aminocarboxymuconate-semialdehyde decarboxylase (EC 4.1.1.45) was downregulated following treatment with the PPARalpha and -delta agonists. The decrease was up to 11-fold compared with controls in the groups treated with high doses of fenofibrate. This supports the link between increased NMN and 4PY excretion and regulation of the tryptophan-NAD+ pathway in the liver. In conclusion, NMN, and possibly other metabolites in the pathway, are potential non-invasive surrogate biomarkers of peroxisome proliferation in the rat.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12944176     DOI: 10.1080/1354750031000149124

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  18 in total

Review 1.  The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball?

Authors:  Julian L Griffin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-01-29       Impact factor: 6.237

2.  Human urinary metabolomic profile of PPARalpha induced fatty acid beta-oxidation.

Authors:  Andrew D Patterson; Ondrej Slanar; Kristopher W Krausz; Fei Li; Constance C Höfer; Frantisek Perlík; Frank J Gonzalez; Jeffrey R Idle
Journal:  J Proteome Res       Date:  2009-09       Impact factor: 4.466

3.  Metabonomics in diabetes research.

Authors:  Johan H Faber; Daniel Malmodin; Henrik Toft; Anthony D Maher; Derek Crockford; Elaine Holmes; Jeremy K Nicholson; Marc E Dumas; Dorrit Baunsgaard
Journal:  J Diabetes Sci Technol       Date:  2007-07

4.  Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus.

Authors:  Andrew D Patterson; Jessica A Bonzo; Fei Li; Kristopher W Krausz; Gabriel S Eichler; Sadaf Aslam; Xenia Tigno; John N Weinstein; Barbara C Hansen; Jeffrey R Idle; Frank J Gonzalez
Journal:  J Biol Chem       Date:  2011-04-12       Impact factor: 5.157

5.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.

Authors:  Yasuo Horie; Akira Suzuki; Ei Kataoka; Takehiko Sasaki; Koichi Hamada; Junko Sasaki; Katsunori Mizuno; Go Hasegawa; Hiroyuki Kishimoto; Masahiro Iizuka; Makoto Naito; Katsuhiko Enomoto; Sumio Watanabe; Tak Wah Mak; Toru Nakano
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

6.  Integrative "omic" analysis of experimental bacteremia identifies a metabolic signature that distinguishes human sepsis from systemic inflammatory response syndromes.

Authors:  Raymond J Langley; Jennifer L Tipper; Shannon Bruse; Rebecca M Baron; Ephraim L Tsalik; James Huntley; Angela J Rogers; Richard J Jaramillo; Denise O'Donnell; William M Mega; Mignon Keaton; Elizabeth Kensicki; Lee Gazourian; Laura E Fredenburgh; Anthony F Massaro; Ronny M Otero; Vance G Fowler; Emanuel P Rivers; Chris W Woods; Stephen F Kingsmore; Mohan L Sopori; Mark A Perrella; Augustine M K Choi; Kevin S Harrod
Journal:  Am J Respir Crit Care Med       Date:  2014-08-15       Impact factor: 21.405

7.  Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation.

Authors:  Yueying Zhen; Kristopher W Krausz; Chi Chen; Jeffrey R Idle; Frank J Gonzalez
Journal:  Mol Endocrinol       Date:  2007-06-05

8.  Production of L-tryptophan-derived catabolites in hepatocytes from streptozotocin-induced diabetic rats.

Authors:  Naho Sasaki; Yukari Egashira; Hiroo Sanada
Journal:  Eur J Nutr       Date:  2009-01-23       Impact factor: 5.614

9.  Metabonomics evaluations of age-related changes in the urinary compositions of male Sprague Dawley rats and effects of data normalization methods on statistical and quantitative analysis.

Authors:  Laura K Schnackenberg; Jinchun Sun; Parvaneh Espandiari; Ricky D Holland; Joseph Hanig; Richard D Beger
Journal:  BMC Bioinformatics       Date:  2007-11-01       Impact factor: 3.169

10.  Application of NMR-based metabolomics for environmental assessment in the Great Lakes using zebra mussel (Dreissena polymorpha).

Authors:  Miki Watanabe; Kathryn A Meyer; Tyler M Jackson; Tracey B Schock; W Edward Johnson; Daniel W Bearden
Journal:  Metabolomics       Date:  2015-02-21       Impact factor: 4.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.